Biocept, Inc.
BIOC
NASDAQ
Last Updated: 6/9/2023 7:59:56 PM
High
Low
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.Biocept, Inc. Company Details
CEO: Mr. Samuel D. Riccitelli
Country: US
Industry: Diagnostics & Research
Website: https://biocept.com
Exchange: NASDAQ Capital Market
IPO\Launch Date: 2014-02-05
Biocept, Inc. Company Executive Details
Dr. Soon Kap Hahn Ph.D.
Founder
Dr. Philippe J. Marchand Ph.D.
Chief Operating Officer
Mr. David S. Moskowitz R.Ph., MBA
Vice President of Strategy & Corporation Communications
Mr. Darrell Taylor Esq.
Senior Vice President, Chief Legal Officer & Chief Compliance Officer
Mr. Michael Terry
Senior Vice President of Corporation Devel.
Biocept, Inc. Latest News
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company's cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture. In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person's brain and spinal cord (the leptomeninges).
Published on: 2023-06-05 09:36:49
Impact on Symbol / Company: BIOC
View News
Why Is Biocept (BIOC) Stock Down 42% Today?
Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock.
Published on: 2023-05-25 08:56:07
Impact on Symbol / Company: BIOC
View News
Biocept shares to commence trading on split-adjusted basis
Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock will begin trading on a split-adjusted basis as of the open of the market on May 17 under Biocept's existing ticker symbol “BIOC.
Published on: 2023-05-17 09:06:54
Impact on Symbol / Company: BIOC
View News
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.
Published on: 2023-04-17 16:47:52
Impact on Symbol / Company: BIOC
View News
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metastases has been enrolled in the FORESEE clinical trial with the company's proprietary cerebrospinal fluid assay CNSide (NCT05414123). In a nutshell, leptomeningeal metastases, or LM, is cancer in your cerebrospinal fluid and membranes that surround your brain and spinal cord (the leptomeninges).
Published on: 2023-03-24 09:01:26
Impact on Symbol / Company: BIOC
View News
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and Interim President and Chief Executive Officer Antonino Morales - Interim Chief Financial Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode.
Published on: 2022-11-28 18:26:06
Impact on Symbol / Company: BIOC
View News
Biocept reports 176% year-over-year jump in orders for CNSide assay
Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines.
Published on: 2022-11-21 16:53:51
Impact on Symbol / Company: BIOC
View News
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the audit committee. This increases board membership to eight for the San Diego-based provider of molecular diagnostic assays, products and services.
Published on: 2022-11-18 08:59:52
Impact on Symbol / Company: BIOC
View News
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
Biocept Inc (NASDAQ:BIOC) said it is participating in a study evaluating biomarkers associated with central nervous system (CNS) metastasis in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. The study will look at cerebrospinal fluid tumor and the immune cell microenvironment to better understand treatment response, prognosis, and treatment resistance that may improve the management of CNS disease in patients with metastatic breast cancer, the company said.
Published on: 2022-11-16 09:27:55
Impact on Symbol / Company: BIOC
View News
Biocept continuing to position itself as 'leader in neurological tumor diagnostics' as it posts second quarter results
Biocept Inc (NASDAQ:BIOC) told investors it was continuing to position itself as a "leader in neurological tumor diagnostics" as the company released second-quarter results, which included the first revenue from a biopharma firm using its CNSide in a clinical trial. Biocept's CNSide cerebrospinal fluid assay can detect cancer cells that have metastasized to the central nervous system.
Published on: 2022-11-11 08:25:37
Impact on Symbol / Company: BIOC
View News
Biocept expands availability of its CNSide assay for most cancers that metastasize to the central nervous system
Biocept Inc (NASDAQ:BIOC) revealed that it has expanded the commercial availability of CNSide, which is based on its proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets, to patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, the San Diego, California-based company's CNSide is a proprietary cerebrospinal fluid (CSF) assay designed to better detect metastatic cancers involving the central nervous system (CNS).
Published on: 2022-10-17 09:27:06
Impact on Symbol / Company: BIOC
View News
Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial
Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord. Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).
Published on: 2022-06-22 09:11:01
Impact on Symbol / Company: BIOC
View News
Grow your Money
We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures
Services we Offer
We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others
Live Market Data
We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you